title: Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for the treatment of peritoneal carcinomatosis in pediatric solid malignancies: a single institution experience.
abstract: BACKGROUND
  Peritoneal carcinomatosis from abdominal tumors is an uncommon condition in children usually associated with dismal prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) following complete macroscopic surgery has been demonstrated to be safe and of benefit in selected cases. Experience in pediatrics is scarce.
  
  
  METHODS
  We retrospectively reviewed the medical files of patients under the age of 18years with an abdominal malignancy and peritoneal carcinomatosis who had been treated with HIPEC in our institution between March 2001 and April 2012. HIPEC had been administered using the open technique with oxaliplatin (300mg/m(2)) and irinotecan (200mg/m(2)) or oxaliplatin alone (460mg/m(2)) in the peritoneal cavity for 30minutes at 43°C and an intravenous perfusion of leucovorin (20mg/m(2)) and 5-fluorouracil (400mg/m(2)).
  
  
  RESULTS
  Nine patients had undergone HIPEC. Grade 3-4 complications had occurred in seven patients and were intraabdominal (n=3) or extraabdominal (n=8). No procedure-related deaths had occurred. Four patients are alive and in complete remission after a median follow-up of 4.9years (1.7-9.6). However one relapsed after HIPEC and required additional salvage therapy.
  
  
  CONCLUSIONS
  HIPEC could be considered in patients with peritoneal carcinomatosis from primary abdominal tumors. Its complications are manageable by an experienced multidisciplinary team. There are four long-term survivors, one after a relapse.
authors.affiliation: Pediatric Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
authors.forename: Francisco
authors.initials: F
authors.lastname: Bautista
authors.affiliation: Oncology Surgery Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Elias
authors.affiliation: Pediatric Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
authors.forename: Claudia
authors.initials: C
authors.lastname: Pasqualini
authors.affiliation: Pediatric Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Valteau-Couanet
authors.affiliation: Pediatric Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France. Electronic address: Laurence.BRUGIERES@gustaveroussy.fr.
authors.forename: Laurence
authors.initials: L
authors.lastname: Brugières
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002648:Child; D065426:Cytoreduction Surgical Procedures / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007274:Injections, Intraperitoneal; D008297:Male; D010534:Peritoneal Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Cancer; Cytoreductive surgery; HIPEC; Pediatrics; Peritoneal carcinomatosis